Clinical Trials Logo

Hepatocellular Carcinoma (HCC) clinical trials

View clinical trials related to Hepatocellular Carcinoma (HCC).

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04235660 Terminated - Clinical trials for Hepatocellular Carcinoma (HCC)

Y90 Radiation Segmentectomy vs SBRT for HCC

SBRT vs Y90
Start date: July 22, 2020
Phase: N/A
Study type: Interventional

The proposed study is a single site, prospective, randomized pilot study to assess the feasibility of recruitment of patients into a trial evaluating the efficacy and tolerability of selective transarterial Y90 radioembolization (radiation segmentectomy) versus stereotactic body radiation therapy (SBRT) for solitary early stage (≤ 3cm) hepatocellular carcinoma (HCC).

NCT ID: NCT03236649 Terminated - Clinical trials for Hepatocellular Carcinoma (HCC)

The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects

Start date: September 20, 2017
Phase: Phase 3
Study type: Interventional

The primary efficacy index of this study is to compare the OS of the two groups.

NCT ID: NCT03144661 Terminated - Ovarian Cancer Clinical Trials

An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies

Start date: May 25, 2017
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability, and determine the maximum tolerated dose of INCB062079 in subjects with advanced hepatocellular carcinoma and other malignancies.

NCT ID: NCT03071094 Terminated - Clinical trials for Hepatocellular Carcinoma (HCC)

A Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC)

Start date: July 27, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This is a study to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC).

NCT ID: NCT01433016 Terminated - Clinical trials for Chronic Liver Disease

Detection of Hepatocellular Carcinoma (HCC) With Octanoate Breath ID Test Compared to MRI

OBT for HCC
Start date: November 2011
Phase: Phase 2
Study type: Interventional

The Exalenz clinical investigation is a multicenter, non-randomized, study of the ¹³C-Octanoate Breath Test (OBT). The present study is a feasibility trial, which aims to evaluate the capability of the OBT measurement to differentiate between presence and absence of HCC determined by Magnetic Resonance Imaging (MRI) in patients with chronic liver disease.